Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin for NAFLD with type 2 diabetes mellitus
ACTRN12624000032550Phase 3Not yet recruiting
- Sponsor
- Abdul Wali Khan University Mardan
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of ertugliflozin in metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Abdul Wali Khan University Mardan. Primary endpoints: Change in liver function profile at 24 weeks, Change in lipid profile at 24 weeks and 1 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
ertugliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ACTRN12624000032550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000032550.